ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, today announced the launch of its latest product: CHO cell–derived recombinant Activin-A, now available for immediate delivery worldwide.

Activin-A is increasingly recognized as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases. Studies have shown that it can help reduce damage and inflammation, making it a vital tool for researchers exploring new treatments and breakthroughs in these critical areas.

“By introducing recombinant Activin-A into our portfolio, we aim to accelerate discoveries in neuroscience, immunology, and regenerative medicine,” said Mr. Nadav Amarant, Managing Director at ProSpecBio. “Our mission is to deliver cutting-edge, reliable proteins that empower researchers and scientists worldwide to push the boundaries of science.”

With its CHO cell–derived purity and reliability, ProSpecBio’s Activin-A recombinant protein provides laboratories and academic institutions with the quality and consistency required for groundbreaking research. This product expands ProSpecBio’s cytokine-related product line, reinforcing its position as a trusted partner to researchers globally.

About ProSpecBio

ProSpecBio is a rapidly advancing biotechnology company specializing in highly purified proteins, serving academic institutions, laboratories, and the broader research community worldwide. With a comprehensive catalog of cytokines, growth factors, and other recombinant proteins, ProSpecBio is committed to advancing life science research by providing innovative and reliable solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918856943/en/

ProSpecBio Launches Activin-A Recombinant Protein, Empowering Global Research in Inflammation and Brain Injury